<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00027664</url>
  </required_header>
  <id_info>
    <org_study_id>ICRF-C00.204</org_study_id>
    <secondary_id>CDR0000069055</secondary_id>
    <secondary_id>EU-20129</secondary_id>
    <nct_id>NCT00027664</nct_id>
  </id_info>
  <brief_title>Interferon Alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer</brief_title>
  <official_title>Interferon Alpha In Combination With Thalidomide In The Treatment Of Metastatic Renal Cell Carcinoma A Randomized Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Thalidomide may&#xD;
      stop the growth of cancer by stopping blood flow to the tumor. It is not yet known if&#xD;
      interferon alfa is more effective with or without thalidomide in treating metastatic kidney&#xD;
      cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to compare the effectiveness of interferon alfa with or&#xD;
      without thalidomide in treating patients who have metastatic kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety of interferon alfa and thalidomide in patients with metastatic&#xD;
           renal cell carcinoma.&#xD;
&#xD;
        -  Compare the relative toxicity of interferon alfa with or without thalidomide in these&#xD;
           patients.&#xD;
&#xD;
        -  Assess the antiangiogenic effect of thalidomide by monitoring the&#xD;
           angiogenesis-associated factors in these patients.&#xD;
&#xD;
        -  Compare, in a preliminary manner, the efficacy of interferon alfa with or without&#xD;
           thalidomide in these patients.&#xD;
&#xD;
        -  Compare the quality of life of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of two&#xD;
      treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive interferon alfa subcutaneously 3 times a week and oral&#xD;
           thalidomide once daily for 12 weeks.&#xD;
&#xD;
        -  Arm II: Patients receive interferon alfa only as in arm I. Treatment in both arms&#xD;
           repeats every 12 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
           Patients in arm II who develop disease progression discontinue interferon alfa and&#xD;
           receive thalidomide only as in arm I.&#xD;
&#xD;
      Quality of life is assessed at baseline and then every 3 weeks during each study course.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 90 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2001</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-angiogenic effect</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life</measure>
  </primary_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic renal cell carcinoma&#xD;
&#xD;
          -  Measurable progressive disease, defined as non-irradiated marker lesions greater than&#xD;
             1 cm&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Neutrophil count greater than 1,500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 10 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST/ALT less than 5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine clearance greater than 50 mL/min OR&#xD;
&#xD;
          -  Edetic acid clearance greater than 40 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No unstable angina or myocardial infarction within the past 6 months&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other prior invasive malignancy except cervical intraepithelial neoplasia or&#xD;
             nonmelanomatous skin cancer&#xD;
&#xD;
          -  No chronic neurological disease causing peripheral neuropathy&#xD;
&#xD;
          -  No diabetes mellitus&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use at least one highly effective method and at least one&#xD;
             additional effective method of contraception for female patients and barrier&#xD;
             contraception for male patients for at least 2 weeks before and during study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior interferon alfa for metastatic renal cell carcinoma&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior systemic chemotherapy for metastatic renal cell carcinoma&#xD;
&#xD;
          -  No concurrent cytotoxic therapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Concurrent local radiotherapy for symptomatic secondary sites of disease allowed if&#xD;
             these sites are not being used as markers of disease response&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other prior systemic treatment for metastatic renal cell carcinoma&#xD;
&#xD;
          -  No concurrent chronic medication known to cause peripheral neuropathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian L. Harris, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Oxford University Hospitals NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>0X3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2002</verification_date>
  <study_first_submitted>December 7, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <keyword>stage IV renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

